BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AGAH - ECPv5.16.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AGAH
X-ORIGINAL-URL:https://dev.agah.eu
X-WR-CALDESC:Events for AGAH
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20070325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20071028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070426
DTEND;VALUE=DATE:20070428
DTSTAMP:20260929T023350
CREATED:20190311T213913Z
LAST-MODIFIED:20190613T203259Z
UID:3126-1177545600-1177718399@dev.agah.eu
SUMMARY:2nd Joint Annual Meeting and 17th AGAH Annual Meeting 2007
DESCRIPTION:Positioning Human Pharmacology for the Future \n\n\n\n	Announcement \n\n\nApril 26-27\, 2007\, Bad Homburg von der Höhe\, Germany \nThe second Joint Annual Meeting of Club Phase 1 and AGAH took place in April 2007 in Bad Homburg von der Höhe and addressed the vital question how to position human pharmacology for the future. More than 300 participants from 10 countries discussed different aspects during the four scientific sessions in various workshops and symposia. \nAGAH and Club Phase 1 were delighted to welcome also their colleagues from the Belgian association of phase I units (BAPU) to the meeting. \n\n\n\n\n\n\n	Introduction \nHuman Pharmacology for the Future\nSecond Joint Annual Meeting Club Phase I and AGAH 2007 \n\n\nThis second joint meeting of Club Phase 1 - the French Associati- on of Early Human Drug Development — and AGAH — the German\nAssociation for Applied Human Pharmacology - addresses a vital question:\n„How to position human pharmacology for the future?“\nWhich role can and should human pharmacology play in the development of new classes of drugs and biologicals?\nThis meeting will attempt to find answers to these questions and also to highlight technical-\, safety- and regulatory issues impacting on clinical development.\nAGAH and Club Phase 1 are delighted to welcome our Belgian Colleagues from BAPU to this meeting and are looking forward to their scientific contributions and collaboration. This will certainly foster the widespread mutual interest for a pan European collaboration of human pharmacologists Positioning \n\n\n\n\n\n\n	Congress Information \nDate:\nApril 26 and 27\, 2007 \nConference venue:\nMARITIM HOTEL BAD HOMBURG\nKurhaushotel/Kongresszentrum\nLudwigstraße 3\n61348 Bad Homburg vor der Höhe\nGermany\nTelephone: +49 (0)6172 660-0\nFax: +49 (0)6172 660-100 \nRegistration:\nINTERCOM Dresden\nAntje Blömeke\nZellescher Weg 3\n01069 Dresden\nGermany\nTelephone +49 (0)351 4633 3014\nFax +49 (0)351 4633 7049\nE-mail: abloemeke@intercom.de\nHomepage: www.agah-web.de \nFees \n  \n250\,00 € Member (early registration)\n275\,00 € Member\n275\,00 € Nonmember (early registration)\n300\,00 € Nonmember\n200\,00 € Junior Scientist\n125\,00 € Junior Poster (Member)\n150\,00 € Junior Poster (Nonmember)\n200\,00 € Day Ticket\n275\,00 € Industry Exposition Staff \nEarly bird reductions applied for registration up to January 31\, 2007.\nFees include admission to all sessions\, lunches and coffee breaks. \n  \nAccommodation:\nA number of rooms at special discounted\nrates are available at the Venue. \n  \n\n\n\n\n	Day 1\, Thursday - April 26\, 2007  \n\n08.30  \nRegistration and coffee \n\n09.00  \nOpening remarks\nPresidents AGAH and Club Phase I \n\nSession I Current approaches in human pharmacology \n\nChair \n Y. Donazzolo\, Gières\, T. Thomsen\, Andernach \n\n09.05  \nPharmacokinetics and bioavailability: Examples from variousbody fluids \nW. Cawello\, Monheim \n\n09.40 \nTolerability and safety: Predictability of QT prolongation in healthy subjects from preclinical experiments \n H. Caplain\, Paris \n\n10.15  \nDose/concentration-effect relationship: Biomarkers in CNS drug development - effects of opioid analgesics \nF. Fliegert\, Aix-la-Chapelle \n\n10.50 \nCoffee break \n\n11.15  \nParallel workshops \n• An introduction to state of the art pharmacokinetics\nW. Cawello\, Monheim\n• PK and PD as predictors of a clinical effect\nJ. Grevel\, Verona\n• Need for and approaches to a European trial subjects database\nB. Schug\, Oberursel\, R. Schäfer\, Francfort\, A. Peremanns\, Brussels\, Y. Donazzolo\, Gières\, T. Thomsen\, Andernach\n• Designs of human pharmacology trials for paediatric populations\nE. Jacqz-Aigrain\, Paris\, H. Seyberth\, Landau\n• Current regulatory developments relevant o human pharmacology in the EU\nI. Klingmann\, Brussels\, C. Schneider\, Langen \n\n12.30  \nLunch break and Poster Session \n\nSession II  \nWhat is human pharmacology expected to deliver in the future? \n\nChair \n K. Breithaupt-Grögler\, Francfort\, A. Patat\, Rennes \n\n14.00  \nFrom understanding the disease to implementing the diagnostic biomarker and the effective treatment—practical examples \n S. Stürzebecher\, Aix-la-Chapelle \n\n14.35 \nDevelopment of meaningful interaction studies for combination therapies \n J. van Gerven\, Leiden \n\n15.10 \nImaging techniques in the early development of new compounds \n P. Danjou\, Paris \n\n15.45  \nCoffee break \n\n16.00  \nRound table discussion\nChair: I. Klingmann\, Brussels\, I. Paty\, Paris \nWill human pharmacology be needed to develop individualized treatments?\nParticipants: D. Austin\, London\, H. Caplain\, Paris\, T. Sudhop\, Bonn\, S. Stürzebecher\, Aix-La-Chapelle\, M. Zühlsdorf\, Basle  \n\n17.15 \nEnd of Day I \n\n18.30 \nConference Dinner Event \n\n\n\n\n	Day 2\, Friday - April 27\, 2007  \nSession III \nChallenges and limitations of human pharmacology \n\nChair \n L. Tritsman\, Brussels\, J. van Gerven\, Leiden \n\n08.30  \nHuman pharmacology for biologicals—first into man \nD. Austin\, London \n\n09.00 \nGenotyping: A reliable predictor for safety and tolerability? \nM. Schwab\, Stuttgart \n\n09.30  \nInterpretation of early safety signals \nM. Sibille\, Lyon \n\n10.00  \nCoffee break \n\n10.30  \nParallel workshops: \n\nMicrodosing: myths and reality; scientific\, regulatory and financial perspectives\nJ. de Hoon\, Leuven\, D. Pegg\, Ann Arbor\, C. Schneider\, Langen\, C. Garner\, Haslington\nPredictability of pharmacological methods\nJ-L. Pinquier\, Paris\nBiomarkers in specific areas\nM. Zühlsdorf\, Basle\nSustainability of the pharmaceutical development pipeline: methods\, facts and perspectives\nW. Seifert\, Berlin\nDo population kinetics work without densedata sampling?\nN.O. Hoem\, Hamburg \n\n\n12.00  \nLunch break and Poster Session \n\nSession IV \nGetting fit for the future of human pharmacology \n\nChair \nH. Caplain\, Paris\, C. Hinze\, Rheinau  \n\n13.30  \nScientific requirements: Perspective of an editor for an international clinical pharmacology journal \nU. Fuhr\, Cologne \n\n14.00 \nOxford debate on how to establish tolerability and safety —MTD versus pharmacological activity \nM. Sibille\, Lyon\, J. van Gerven\, Leiden \n\n14.45  \nNew regulatory requirements for first into man studies in Germany and France \nT. Sudhop\, BfArM\, Bonn\, D. Tremblay AFSSAPS\, Paris \n\n15.45 \nClosing remarks \nH. Fuder\, Hamburg \n\n\n\n\n	Presentations of the Annual Meeting 2007 \n\nD. Austin\nD._Austin_25.05.07\nHuman pharmacology for biologicals – First into man studies \n\nH. Caplain\nCPI_AGAH_HC_042207\nTolerability and safety: Predictability of QT prolongation in healthy subjects from preclinical experiments \n\nW. Cawello\nW._Cawello__2__25.05.07_01\nPharmacokinetics and bioavailability derived from various body fluids \n\nPh. Danjou\nPh._Danjou_21.06.07_01\nImaging in Early Drug Development \n\nF. Fliegert\nF._Fliegert__30.05.07_01\nBiomarkers in CNS drug development \n\nJ. van Gerven\nDevelopment_Of_Meaningful_Interaction_Studies_For_Combination_Therapies\nDevelopment of Meaningful Interaction Studies for Combination Therapies \n\nJ. Grevel\nJ.Grevel_25.05.07_01\nPK and PD as predictors of clinical effect \n\nCh. Schneider\nCh._Schneider_BAPU_WS_31.05.07\nHandling of First-in-man trials: regulatory rethink? \n\nCh. Schneider\nCh._Schneider__2__WS_31.05.07\nCurrent regulatory developments relevant to human \n\nB. Schug\nB._Schug_25.05.07\nNeed for a European Trial Data Base Introductory Remarks \n\nW. Seifert\nH._Seyberth_26.05.07_WS_I_01\nWorkshop: Designs of human pharmacology trials for paediatric populations \n\nM. Sibille\nM._Sibille_25.05.07_EarlySafety_01\nInterpretation of early safety signals \n\nM. Sibille\nM._Sibille_25.05.07_MTD_Oxford_debate_01\nIs priority to MTD – maximal tolerated dose – the best way? \n\nCh. Steffen\nC._Steffen_FIM\nClinical Trial Authorisation in Germany for First-in-Man Trials with NCEs \n\nD. Tremblay\nD._Tremblay_26.05.07\nNew regulatory requirements for first into man studies in France
URL:https://dev.agah.eu/event/2nd-joint-annual-meeting-and-17th-agah-annual-meeting-2007/
LOCATION:Annual Meeting 2007\, Bad Homburg\, Deutschland
CATEGORIES:Annual Meetings
END:VEVENT
END:VCALENDAR